BioXcel Corporation
BioXcel LLC is an AI-enabled drug discovery and development company that applies machine learning, natural language processing and biomedical data integration to accelerate target discovery, asset prioritization, repurposing and clinical development. The organization offers services to biopharma partners and operates a proprietary AI platform used to analyze literature, clinical and real-world data to support R&D decision making. The company has supported programs that proceeded to regulatory approval and maintains a family of affiliated companies focused on AI-driven drug discovery and therapeutics.
Industries
Nr. of Employees
small (1-50)
BioXcel Corporation
555 Long Wharf Drive, 12th Floor, New Haven, CT 06511, USA
Patents
Use of ubiquitin-proteasome system inhibitors for treatment of tumors associated with neurofibromatosis type-2
US-10610563-B2
View DetailsMethods for reformulating and repositioning pharmaceutical data and devices thereof
US-10572631-B2
View Details
Use of ubiquitin-proteasome system inhibitors for treatment of tumors associated with neurofibromatosis type-2
US-10610563-B2
View DetailsMethods for reformulating and repositioning pharmaceutical data and devices thereof
US-10572631-B2
View DetailsProducts
Proprietary AI platform for drug discovery
A multi-modal artificial intelligence platform that integrates literature, clinical trials, genomic and intervention data to generate hypotheses, knowledge graphs and predictive models for discovery and development.
Proprietary AI platform for drug discovery
A multi-modal artificial intelligence platform that integrates literature, clinical trials, genomic and intervention data to generate hypotheses, knowledge graphs and predictive models for discovery and development.
Services
End-to-end AI-enabled discovery and development services combining human scientific expertise with proprietary machine-learning models to accelerate target-to-clinic programs.
Target identification, pathway analysis and biomarker discovery using integrated literature and omics data to build a preclinical foundation.
Portfolio-level analyses including competitive landscape, trial benchmarking, TPP development, market sizing and NPV/sales forecasting to inform prioritization.
Technical due diligence, asset benchmarking, value proposition development and deal strategy support for licensing transactions.
Indication expansion, drug repositioning and regulatory pathway support (including 505(b)(2) strategies) to extend asset value.
Flexible collaboration models including fully managed discovery programs, joint development and target scouting powered by AI.
End-to-end AI-enabled discovery and development services combining human scientific expertise with proprietary machine-learning models to accelerate target-to-clinic programs.
Target identification, pathway analysis and biomarker discovery using integrated literature and omics data to build a preclinical foundation.
Portfolio-level analyses including competitive landscape, trial benchmarking, TPP development, market sizing and NPV/sales forecasting to inform prioritization.
Technical due diligence, asset benchmarking, value proposition development and deal strategy support for licensing transactions.
Indication expansion, drug repositioning and regulatory pathway support (including 505(b)(2) strategies) to extend asset value.
Flexible collaboration models including fully managed discovery programs, joint development and target scouting powered by AI.
Expertise Areas
- AI-driven drug discovery
- Target identification and validation
- Drug repurposing and indication expansion
- Clinical development optimization and patient stratification
Key Technologies
- Machine learning and proprietary AI models
- Natural language processing (NLP)
- Knowledge graphs
- Multi-modal data integration (genomic, clinical, literature)
News & Updates
Press release describing an expanded collaboration to provide AI-driven discovery capabilities to Kyowa Kirin's R&D teams (related family company activity).
Announcement of a collaboration to create therapeutics for immune diseases using validated AI-based discovery methods (family company activity).
Regulatory approval of an orally dissolving sublingual dexmedetomidine film for treatment of acute agitation associated with schizophrenia or bipolar disorder; cited as a program advanced using the company's AI-enabled approach.
Company-reported track record of over 350 projects, including a program that reached regulatory approval.
Press release describing an expanded collaboration to provide AI-driven discovery capabilities to Kyowa Kirin's R&D teams (related family company activity).
Announcement of a collaboration to create therapeutics for immune diseases using validated AI-based discovery methods (family company activity).
Regulatory approval of an orally dissolving sublingual dexmedetomidine film for treatment of acute agitation associated with schizophrenia or bipolar disorder; cited as a program advanced using the company's AI-enabled approach.
Company-reported track record of over 350 projects, including a program that reached regulatory approval.